A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis
Latest Information Update: 07 Nov 2022
At a glance
- Drugs MRT-5005 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Acronyms RESTORE-CF
- Sponsors Translate Bio
- 06 May 2021 According to a Translate Bio media release, the company completes enrollment and dosing in this trial
- 06 May 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2021 According to a Translate Bio media release, the company will host a conference call and webcast today at 4:30 PM ET to discuss the second interim results from the single-ascending and multiple ascending dose portions of its Phase 1/2 clinical trial of MRT5005 in patients with CF.